Tradestie Institutional Equity Comparison Engine

CING vs DRMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CING Overall Edge

CING Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cingulate Inc. Common Stock (CING) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DRMA at N/M Forward P/E and -13082.3% operating margin (+0.0% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against DRMA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CING N/M vs DRMA N/M Fwd P/E
Growth & Margin Winner CING
Op Margin 0.0% vs -13082.3% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CING
1Y +36.4% vs -81.1% ยท 52W Pos 18% vs 0%
Options & Structure Winner CING
BREAKDOWN (16th %ile IV) vs UNCLASSIFIED (N/A IV)
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
1M Return +9.17%
1Y Return +36.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
DRMA NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-3.14% 1D
Market Cap $3.1M
1M Return -32.59%
1Y Return -81.12%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 33.0 Fund 46.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CING +36.39% DRMA -81.12% Spread: +117.51 pp (CING Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CING TTM Op. Margin: 0.0% DRMA TTM Op. Margin: -13082.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs DRMA. Trailing 12-month operating profitability (CING 0.0% vs DRMA -13082.3%) and valuation multiples (CING N/M vs DRMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CING (5) vs DRMA (1)
Institutional Metric CING DRMA Criterion Row Winner
Market Capitalization Scale $62.5M $3.1M Larger Scale CING
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% -13082.3% Higher Margin CING
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -198.7% -241.5% Higher ROE CING
52-Week Range Position Momentum 18% ($3โ€“$12) 0% ($1โ€“$5) Stronger Trend CING
Beta / 30D Volatility Risk Regime 1.13ฮฒ ยท 117% Vol 1.10ฮฒ ยท 112% Vol Lower Realized Risk DRMA
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite CING

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CING vs DRMA Buy Guide
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DRMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DRMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CING nor DRMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.